Observational analysis shows similar efficacy and safety of CAR-T therapy in older adults with relapsed or refractory multiple myeloma, indicating potential for broader use.
Key Points
Efficacy and safety of CAR-T therapy for older adults align with younger cohorts' outcomes.
Median progression-free survival for older patients was 28.7 months with cilta-cel, indicating potential benefits.
Observational analysis across 15 centers assessed clinical outcomes for patients aged 75 and older receiving standard-of-care BCMA CAR-T.
Highlighted the importance of including older adults in CAR-T therapy conversation, noting low rates of severe adverse effects.